Symbols / VRPX $0.00 +0.00% Virpax Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • PNK
VRPX Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Jatinder Dhaliwal
Exch · Country PNK · United States
Market Cap 497.00
Enterprise Value -1.51M
Income -12.07M
Sales —
FCF (ttm) -12.26M
Book/sh -1.53
Cash/sh 1.42
Employees 2
Insider 10d —
IPO Feb 17, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.00
PEG —
P/S —
P/B -0.00
P/C —
EV/EBITDA —
EV/Sales —
Quick Ratio 0.61
Current Ratio 0.63
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -71.00
EPS next Y -0.90
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2025-03-03
Earnings (prior) 2025-03-03
ROA -135.01%
ROE -23.65%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 1.24M
Shs Float 1.05M
Insider Own 0.00%
Instit Own 0.00%
Short Float 1.81%
Short Ratio 0.04
Short Interest 23.08K
52W High 0.48
vs 52W High -99.92%
52W Low 0.00
vs 52W Low 300.00%
Beta 2.56
Impl. Vol. —
Rel Volume 0.11
Avg Volume 444.00
Volume 51.00
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.00
Price $0.00
Change 0.00%
About

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also include AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-177.62
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2024-10-09 down Maxim Group Buy → Hold —
2024-07-19 up Maxim Group Hold → Buy $3
2024-05-22 down Maxim Group Buy → Hold —
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
12.08
-28.69%
16.94
-22.46%
21.85
+81.66%
12.03
Research And Development
5.82
+13.71%
5.12
-52.45%
10.76
+122.41%
4.84
Selling General And Administration
6.26
-47.04%
11.82
+6.67%
11.08
+54.21%
7.19
General And Administrative Expense
6.26
-47.04%
11.82
+6.67%
11.08
+54.21%
7.19
Salaries And Wages
—
0.34
—
—
Other Gand A
6.26
-45.50%
11.49
+3.65%
11.08
+54.21%
7.19
Total Expenses
12.08
-28.69%
16.94
-22.46%
21.85
+81.66%
12.03
Operating Income
-12.08
+28.69%
-16.94
+22.46%
-21.85
-81.66%
-12.03
Total Operating Income As Reported
-12.08
+23.01%
-15.69
+28.18%
-21.85
-81.66%
-12.03
EBITDA
-11.96
+29.38%
-16.94
+22.46%
-21.85
-82.60%
-11.96
Normalized EBITDA
-11.96
+34.23%
-18.19
+16.73%
-21.85
-82.60%
-11.96
EBIT
-11.96
+29.38%
-16.94
+22.46%
-21.85
-82.60%
-11.96
Total Unusual Items
—
1.25
—
—
Total Unusual Items Excluding Goodwill
—
1.25
—
—
Special Income Charges
—
1.25
—
—
Other Special Charges
—
-1.25
—
—
Net Income
-12.07
+20.56%
-15.19
+29.84%
-21.65
-79.58%
-12.06
Pretax Income
-12.07
+20.56%
-15.19
+29.84%
-21.65
-79.58%
-12.06
Net Non Operating Interest Income Expense
-0.10
—
0.00
+100.00%
-0.09
Interest Expense Non Operating
0.10
—
0.00
-100.00%
0.09
Net Interest Income
-0.10
—
0.00
+100.00%
-0.09
Interest Expense
0.10
—
0.00
-100.00%
0.09
Other Income Expense
0.12
-93.35%
1.75
+800.29%
0.19
+212.26%
0.06
Other Non Operating Income Expenses
0.12
-76.72%
0.50
+157.33%
0.19
+212.26%
0.06
Tax Provision
—
0.00
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-12.07
+20.56%
-15.19
+29.84%
-21.65
-79.58%
-12.06
Net Income From Continuing Operation Net Minority Interest
-12.07
+20.56%
-15.19
+29.84%
-21.65
-79.58%
-12.06
Net Income From Continuing And Discontinued Operation
-12.07
+20.56%
-15.19
+29.84%
-21.65
-79.58%
-12.06
Net Income Continuous Operations
-12.07
+20.56%
-15.19
+29.84%
-21.65
-79.58%
-12.06
Normalized Income
-12.07
+26.60%
-16.44
+24.07%
-21.65
-79.58%
-12.06
Net Income Common Stockholders
-12.07
+20.56%
-15.19
+29.84%
-21.65
-79.58%
-12.06
Diluted EPS
—
-324.25
+29.89%
-462.50
-2.21%
-452.50
Basic EPS
—
-324.25
+29.89%
-462.50
-2.21%
-452.50
Basic Average Shares
—
0.05
+0.00%
0.05
+75.40%
0.03
Diluted Average Shares
—
0.05
+0.00%
0.05
+75.40%
0.03
Diluted NI Availto Com Stockholders
-12.07
+20.56%
-15.19
+29.84%
-21.65
-79.58%
-12.06
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Assets
1.56
-83.84%
9.63
-51.06%
19.67
-50.28%
39.57
Current Assets
1.56
-83.84%
9.63
-51.06%
19.67
-50.28%
39.57
Cash Cash Equivalents And Short Term Investments
1.51
-83.45%
9.14
-51.87%
19.00
-48.44%
36.84
Cash And Cash Equivalents
1.51
-83.45%
9.14
-51.87%
19.00
-48.44%
36.84
Cash Financial
1.51
-83.45%
9.14
-51.87%
19.00
-48.44%
36.84
Prepaid Assets
0.00
-98.89%
0.42
-35.74%
0.65
+155.24%
0.26
Current Deferred Assets
0.00
0.00
—
—
Other Current Assets
0.03
-48.18%
0.07
+165.27%
0.03
-98.98%
2.47
Total Non Current Assets
0.00
0.00
0.00
0.00
Non Current Deferred Assets
—
—
—
0.00
Total Liabilities Net Minority Interest
2.47
-67.91%
7.69
+148.63%
3.09
+48.23%
2.09
Current Liabilities
2.47
-67.91%
7.69
+148.63%
3.09
+48.23%
2.09
Payables And Accrued Expenses
2.47
+45.77%
1.69
+54.76%
1.09
-47.57%
2.09
Payables
0.04
+122.44%
0.02
-50.97%
0.04
+89.73%
0.02
Other Payable
0.04
+122.44%
0.02
-50.97%
0.04
+89.73%
0.02
Current Accrued Expenses
2.43
+44.93%
1.68
+58.53%
1.06
-48.89%
2.07
Total Tax Payable
—
—
—
0.01
Current Deferred Liabilities
—
—
—
0.00
Other Current Liabilities
—
6.00
+200.00%
2.00
—
Total Non Current Liabilities Net Minority Interest
0.00
0.00
0.00
0.00
Stockholders Equity
-0.91
-147.24%
1.93
-88.33%
16.58
-55.77%
37.48
Common Stock Equity
-0.91
-147.24%
1.93
-88.33%
16.58
-55.77%
37.48
Capital Stock
0.00
+1141.67%
0.00
+0.00%
0.00
-89.74%
0.00
Common Stock
0.00
+1141.67%
0.00
+0.00%
0.00
-89.74%
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
0.60
+1171.11%
0.05
-0.02%
0.05
0.00%
0.05
Ordinary Shares Number
0.60
+1171.11%
0.05
-0.02%
0.05
0.00%
0.05
Additional Paid In Capital
70.70
+15.00%
61.48
+0.89%
60.93
+1.24%
60.19
Retained Earnings
-71.61
-20.27%
-59.54
-34.25%
-44.35
-95.36%
-22.70
Total Equity Gross Minority Interest
-0.91
-147.24%
1.93
-88.33%
16.58
-55.77%
37.48
Total Capitalization
-0.91
-147.24%
1.93
-88.33%
16.58
-55.77%
37.48
Working Capital
-0.91
-147.24%
1.93
-88.33%
16.58
-55.77%
37.48
Invested Capital
-0.91
-147.24%
1.93
-88.33%
16.58
-55.77%
37.48
Net Tangible Assets
-0.91
-147.24%
1.93
-88.33%
16.58
-55.77%
37.48
Tangible Book Value
-0.91
-147.24%
1.93
-88.33%
16.58
-55.77%
37.48
Interest Payable
—
—
—
0.00
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Operating Cash Flow
-16.71
-69.61%
-9.85
+44.79%
-17.85
-22.72%
-14.54
Cash Flow From Continuing Operating Activities
-16.71
-69.61%
-9.85
+44.79%
-17.85
-22.72%
-14.54
Net Income From Continuing Operations
-12.07
+20.56%
-15.19
+29.84%
-21.65
-79.58%
-12.06
Stock Based Compensation
0.13
-75.27%
0.54
-26.88%
0.75
-23.53%
0.97
Operating Gains Losses
—
—
—
-0.06
Change In Working Capital
-4.78
-199.78%
4.79
+56.62%
3.06
+190.00%
-3.40
Change In Prepaid Assets
0.44
+131.96%
0.19
-90.67%
2.05
+175.66%
-2.71
Change In Payables And Accrued Expense
0.78
+29.35%
0.60
+160.36%
-0.99
-44.60%
-0.69
Change In Payable
—
—
—
-0.69
Change In Account Payable
—
—
—
-0.69
Change In Other Current Liabilities
-6.00
-250.00%
4.00
+100.00%
2.00
0.00
Financing Cash Flow
9.08
0.00
0.00
-100.00%
51.33
Cash Flow From Continuing Financing Activities
9.08
0.00
0.00
-100.00%
51.33
Net Issuance Payments Of Debt
—
—
0.00
+100.00%
-1.50
Issuance Of Debt
—
—
0.00
-100.00%
0.10
Repayment Of Debt
—
—
0.00
+100.00%
-1.60
Long Term Debt Issuance
—
—
—
0.10
Long Term Debt Payments
—
—
—
-1.60
Net Long Term Debt Issuance
—
—
—
-1.50
Short Term Debt Issuance
—
—
0.00
-100.00%
0.10
Short Term Debt Payments
—
—
0.00
+100.00%
-1.60
Net Short Term Debt Issuance
—
—
0.00
+100.00%
-1.50
Net Common Stock Issuance
6.32
0.00
0.00
-100.00%
58.02
Proceeds From Stock Option Exercised
2.77
0.00
—
—
Net Other Financing Charges
—
—
—
-5.19
Changes In Cash
-7.63
+22.58%
-9.85
+44.79%
-17.85
-148.51%
36.79
Beginning Cash Position
9.14
-51.87%
19.00
-48.44%
36.84
+67134.82%
0.05
End Cash Position
1.51
-83.45%
9.14
-51.87%
19.00
-48.44%
36.84
Free Cash Flow
-16.71
-69.61%
-9.85
+44.79%
-17.85
-22.72%
-14.54
Interest Paid Supplemental Data
—
—
0.00
-100.00%
0.36
Income Tax Paid Supplemental Data
—
—
0.00
0.00
Common Stock Issuance
6.32
0.00
0.00
-100.00%
58.02
Issuance Of Capital Stock
6.32
0.00
0.00
-100.00%
58.02
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category